Abstract:Abstract Unresolved inflammation plays a critical role in bladder cancer initiation and progression. Chemotherapy (e.g. gemcitabine and cisplatin), the standard of care for advanced bladder cancer, disrupts inflammation resolution and is only partially effective in preventing tumor recurrence after treatment. Immunotherapy has emerged as a potential treatment option for bladder cancer patients, however it is ineffective in 80% of patients and can induce a pro-inflammatory cytokine storm. Therefore, there is a critical unmet medical need to improve chemotherapy and immunotherapy in bladder cancer. To address this, we have developed dual COX-2/sEH inhibitors (e.g. PTUPB). This lead compound is representative of a newly patented class of “dual acting” molecules that target two important enzymes in the arachidonic acid cascade with nanomolar binding affinity: cyclooxygenase-2 (COX-2) and soluble epoxide hydrolase (sEH). Oral dosing of PTUPB is well-tolerated in animal models. Since chemotherapy and immunotherapy both induce tumor-promoting inflammation via an eicosanoid/cytokine storm, we hypothesized that dual COX-2/sEH inhibition would enhance immunotherapy in experimental bladder cancer via anti-inflammatory mechanisms. When syngeneic (MB49) bladder tumors reached ~200 mm3 in immunocompetent mice, treatment was initiated with PTUPB, anti-CTLA-4, anti-PD1, gemcitabine & cisplatin, or various combinations thereof. Here we demonstrate that chemotherapy and/or immunotherapy stimulated sEH and COX-2 expression in tumor tissue which was counter-regulated by PTUPB. While monotherapy treatment with PTUPB, gemcitabine & cisplatin, anti-PD1 or anti-CTLA-4 suppressed tumor growth compared to control, the tumors escaped single treatments by the end of the study. Remarkably, dual COX-2/sEH inhibition in combination with chemotherapy (gemcitabine and cisplatin) and/or immune checkpoint blockade (anti-CTLA-4 or anti-PD1) induced sustained tumor regression via synergistic anti-tumor activities. Chemotherapy and/or immunotherapy induced the expression of ER stress response genes (e.g. BiP and CHOP) and angiogenic factors (e.g. EGF and VEGF-C) in bladder cancer tissue, which were repressed by PTUPB. PTUPB also prevented chemotherapy-induced toxicity and prolonged survival in an orthotopic MB49 tumor model. Taken together, our results demonstrate dual COX-2/sEH inhibition as a novel therapeutic approach to enhance immunotherapy in bladder cancer without overt toxicity. Citation Format: Kimberly Lupita Vazquez, Eva Rothenberger, Weicang Wang, Sung Hee Hwang, Diane R. Bielenberg, Bruce D. Hammock, Dipak Panigrahy. Dual COX-2/sEH inhibition enhances immunotherapy and chemotherapy to induce bladder cancer regression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3924.

Inhibition of KDM4A restricts SQLE transcription and induces oxidative stress imbalance to suppress bladder cancer

Histone H3K36me2 demethylase KDM2A promotes bladder cancer progression through epigenetically silencing RARRES3

Thymoquinone Suppresses the Proliferation, Migration and Invasiveness through Regulating ROS, Autophagic Flux and miR-877-5p in Human Bladder Carcinoma Cells.

Lethal Activity of BRD4 PROTAC Degrader QCA570 Against Bladder Cancer Cells

Carcinogenesis promotion in oral squamous cell carcinoma: KDM4A complex-mediated gene transcriptional suppression by LEF1

Loss of KDM6A-mediated genomic instability and metabolic reprogramming differentially regulates responses to immune checkpoint therapy and chemotherapy in bladder cancer.

KDM1A epigenetically enhances RAD51 expression to suppress the STING-associated anti-tumor immunity in esophageal squamous cell carcinoma

MTX-211 Inhibits GSH Synthesis Through Keap1/NRF2/GCLM Axis and Exerts Antitumor Effects in Bladder Cancer.

Highly Stable Selenadiazole Derivatives Induce Bladder Cancer Cell Apoptosis and Inhibit Cell Migration and Invasion Through the Activation of ROS-mediated Signaling Pathways

Epigenetic Inactivation of KLF4 is Associated with Urothelial Cancer Progression and Early Recurrence

Depletion of Squalene Epoxidase in Synergy with Glutathione Peroxidase 4 Inhibitor RSL3 Overcomes Oxidative Stress Resistance in Lung Squamous Cell Carcinoma

Targeting KDM4A epigenetically activates tumor-cell-intrinsic immunity by inducing DNA replication stress

Knockdown of SIRT1 Suppresses Bladder Cancer Cell Proliferation and Migration and Induces Cell Cycle Arrest and Antioxidant Response Through FOXO3a-Mediated Pathways.

Targeting squalene epoxidase interrupts homologous recombination via the ER stress response and promotes radiotherapy efficacy.

Inhibition of autophagy can promote the apoptosis of bladder cancer cells induced by SC66 through the endoplasmic reticulum stress pathway

Down-regulation of Sphk2 Suppresses Bladder Cancer Progression

Abstract 3924: Dual COX-2/sEH inhibition enhances immunotherapy and chemotherapy to induce bladder cancer regression

Inhibition of G9a by a Small Molecule Inhibitor, UNC0642, Induces Apoptosis of Human Bladder Cancer Cells

Abstract 3808: TM4SF1 Regulates Cell Cycle and ROS Status in Bladder Cancer Cells by Targeting FOXO3a Via PPARγ-SIRT1 Negative Feedback Loop

BRD4 Targets the KEAP1-Nrf2-G6PD Axis and Suppresses Redox Metabolism in Small Cell Lung Cancer

Modification of Lysine-260 2-Hydroxyisobutyrylation Destabilizes ALDH1A1 Expression to Regulate Bladder Cancer Progression